Ablexis, LLC

The Ablexis, LLC and AlivaMab Biologics (AMB) team appreciated all the interest we received during last week’s East Coast Antibody HubXChange!  AMB’s VP of Antibody Discovery, Jane Seagal, was kept busy working triple duty with the keynote presentation, a poster, and a round table discussion, all showcasing: ·  Successful discovery of diverse antibody panels for CLC, human VH single-domain, membrane multispanners, and TCRm antibodies enabled by Ablexis’ suite of ten different AlivaMab® Mouse strains combined with AMB’s discovery platforms ·  Successful engineering of multispecific antibodies enabled by AMB’s matrix-based engineering platform, amenable across formats and functions, including our validated off-the-shelf human CD3 antibodies, TCRm, human VH single-domain, and common light chain antibodies If you were unable to attend or connect with us in person, please don't hesitate to get in touch!   AlivaMab Biologics offers collaborative, adaptable, and customized solutions for the discovery and engineering of next generation biotherapeutics. Get in touch by emailing us at [email protected].  

AlivaMab Biologics and Ablexis congratulate our partner, Anaveon, on the FDA’s approval of the IND for the ANV600-001(EXPAND) Phase I/II clinical study. “ANV600 uses a non-blocking anti-PD-1 antibody to target a powerful IL-2Rβ/γ selective IL-2 agonist to tumor-specific T cells, resulting in their proliferation and increase of tumor-killing potential. ANV600 is designed to administer in combination with approved PD-1 checkpoint inhibitors, thus enabling optimal dosing of IL-2 agonism and PD-1 blockade to maximize therapeutic benefit.”  https://t.ly/3yD_m ANV600 is just one member of the expanding pipeline of innovative biologics drug candidates discovered at AlivaMab Biologics and poised to change treatment paradigms for patients. Connect with us at [email protected] to learn how we can enable success for your biologics drug discovery and engineering projects.

Ablexis, LLC and AlivaMab Biologics (AMB) will be attending East Coast Antibody HubXChange in Boston next week!  Jane Seagal will showcase our comprehensive approach for the discovery and engineering of the next generation of biotherapeutics: · Keynote presentation will highlight how AlivaMab® Mouse strains combined with AMB’s discovery platforms enable successful discovery of diverse antibody panels for CLC, human single-domain, membrane multispanners, and TCRm antibodies for CD3 T-cell engagers · Poster presentation will highlight our platforms for the discovery of TCR mimic antibodies, human VHH, and common light chain antibodies for engineering into bispecific formats   Jane will also lead a round table “Technologies accelerating engineering into advanced modalities” that will be sure to spark interesting discussions! If you’d like to learn more, please request to meet via the HubXChange organizers. Otherwise, please reach out to us at [email protected] or [email protected].

Great opportunity to join a fantastic team!

AlivaMab Biologics ("AMB”) has launched an innovative common light chain ("CLC") antibody discovery platform that employs the better aspects of in vivo and in vitro antibody discovery approaches to efficiently deliver high quality antibodies for bispecific antibody engineering.   Standard approaches for discovery of common light chain bispecific antibodies start with either common light chain transgenic animals or naïve in vitro display libraries. Both methods have limitations due to the restrictions of using a single fixed common light chain.   The in vivo approach utilizes animals transgenic for fixed V-J pre-rearranged light chain(s). Studies have shown that paucity of diversity in the light chain can limit the robustness and diversity of immune responses against antigens. Moreover, it is difficult to suppress completely somatic hypermutation processes acting on the fixed “common” light chain, resulting in IgG hits with “uncommon” light chains. The in vitro display CLC workflows utilize naïve V heavy repertoires paired with a single fixed VL. Deficiencies with this strategy include limited epitope diversity in the hits and a requirement for multiple rounds of affinity maturation of the heavy chain to attain desired affinity, along with the typical issues associated with display platforms, which may include developability and specificity issues.   AMB’s workflow for CLC antibody discovery creates a more expedient path to deliver a panel of highly diverse and specific common light chain binders by implementing a more flexible approach that includes: · Immunizing multiple AlivaMab® Mouse-XKL strains (Ablexis) to generate a diverse pool of in vivo matured secondary (IgG) immune VH repertoires · NGS analyses of the IgG immune repertoire of the immunized AlivaMab Mice to identify optimal, e.g., more frequently used, light chains to pair with the recovered VH repertoire · Construction of two-to-three phage display libraries, each comprising the diverse in vivo matured VH repertoire of the IgG response paired with a rationally selected fixed light chain in a Fab format AlivaMab Biologics’ innovative common light chain discovery and engineering strategies facilitate the development of the next generation of advanced biologics modalities. Working collaboratively with our partners, we deliver therapeutic quality candidates meeting design goals and fitness for subsequent bispecific antibody development.   For more information, please contact AlivaMab Biologics at [email protected]

Excited to kick off Day 1 at Swiss Biotech! 🎉 Just touched down in the heart of Switzerland after a dynamic trip to Japan, and it's straight into the mix of biotech advances. I'm keen to engage in discussions on how AlivaMab Biologics is a trusted external discovery partner for your new and existing biologics drug discovery projects. 🧬✨ If you see me making my rounds at the event, don't hesitate to say hi – I'm here for the conversations and connections! I'll also be here tomorrow, hopefully bright-eyed despite the jet lag! 😊 P.S.: Still mastering the art of the selfie, so let's chat face-to-face instead, right? 😄 #SwissBiotech #Networking #ScienceCollaboration #JetLagChronicles

AlivaMab Biologics (“AMB”) has launched a platform workflow for the discovery of TCR mimic (“TCRm”) antibodies. TCRm antibodies make “druggable” a myriad of previously “antibody undruggable” intracellular tumor antigens, e.g., transcription factors, nuclear proteins, viral proteins, and other classes of oncoproteins. TCRm antibodies combine the benefit of recognizing intracellular epitopes in the context of MHC, like TCRs, with the benefits of potency, pharmacologic properties, and versatility of mAbs. This greatly expands the potential targets for antibody-based cancer immunotherapy, with applications such as T-cell engagers, CARs, and payload-delivery. However, the discovery, engineering, and validation of safe and effective TCRm antibody therapeutics requires great care. The generation of highly specific TCRm antibodies is known to be a difficult task. First, antibodies specific for the peptide-MHC complex are less frequent because the MHC itself is larger in size and therefore more immunogenic than the target peptide displayed in the MHC. Second, the tumor-derived peptide antigen may have few amino acid differences compared to peptide/MHC complexes from healthy tissues, meaning that off-target binding of non-specific TCRm antibodies could result in damage to healthy tissues. AMB’s platform process for TCRm antibody discovery quickly delivers a panel of highly specific TCRm antibody sequences, by employing: · Ablexis, LLC’ AlivaMab® Mouse XKL strains for expansive molecular diversity · An immunization protocol tailored for each TCRm target peptide/MHC complex · A battery of stringent cell-based peptide/MHC binding screens, finishing with a cell-based screen of an X-scan peptide library to confirm peptide-specificity These highly specific TCRm antibodies are ready for engineering and testing as potent T-cell-engaging bispecific molecules using our diverse panel of pre-validated CD3-binding arms or deployed into other advanced biologics modalities of our partners’ choice. For more information, please contact AlivaMab Biologics at [email protected]